Finance

Lists
Why is 3696 up 3,88%?
Dive Deeper
3696:HKG
Insilico Medicine Cayman TopCo
39,10 HKD
+3,88%
(+1,46) 1D
16 ოქტ, 16:08:14 GMT+8  ·   HKD
All symbols
SymbolPriceChange% Change
Generating top insights for 3696...
Open
39,16 HKD
High
40,28 HKD
Low
38,12 HKD
Mkt. cap
22,88 მლრდ.
Avg. vol.
15,66 მლნ.
Volume
15,71 მლნ.
52-wk high
80,90 HKD
52-wk low
29,98 HKD
EPS
-4,20 HKD
Shares outstanding
557,42 მლნ.
No. of employees
333
Open
39,16 HKD
High
40,28 HKD
Low
38,12 HKD
Mkt. cap
22,88 მლრდ.
Avg. vol.
15,66 მლნ.
Volume
15,71 მლნ.
52-wk high
80,90 HKD
52-wk low
29,98 HKD
EPS
-4,20 HKD
Shares outstanding
557,42 მლნ.
No. of employees
333
News stories
From web sources and news partners
Profile
Insilico Medicine is a biotechnology company headquartered in Boston, Massachusetts, with additional facilities in Pak Shek Kok, Hong Kong in Hong Kong Science Park near the Chinese University of Hong Kong, and in New York, at The Cure by Deerfield. The company applies genomics, big data analysis, and deep learning for in silico drug discovery. Wikipedia
About Insilico Medicine Cayman TopCo
CEOფენგ რენ | ალექს ჟავორონკოვი
Employees333
Founded2014
Headquarters-
SectorHealth care
Last report
26 აგვ. 2026
Fiscal period
Q2 2026
- / -
Revenue / Est. (USD)
53,15 მლნ. / -
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
14,39 მლნ.
14,39 მლნ.
53,15 მლნ.
53,15 მლნ.
Cost of goods sold
2,98 მლნ.
2,98 მლნ.
5,17 მლნ.
5,17 მლნ.
Cost of revenue
2,98 მლნ.
2,98 მლნ.
5,17 მლნ.
5,17 მლნ.
Research and development expenses
22,90 მლნ.
22,90 მლნ.
24,66 მლნ.
24,66 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7,05 მლნ.
7,05 მლნ.
9,47 მლნ.
9,47 მლნ.
Operating expense
30,23 მლნ.
30,23 მლნ.
33,85 მლნ.
33,85 მლნ.
Total operating expenses
33,20 მლნ.
33,20 მლნ.
39,02 მლნ.
39,02 მლნ.
Operating income
-18,81 მლნ.
-18,81 მლნ.
14,14 მლნ.
14,14 მლნ.
Other non operating income
-149,82 მლნ.
-149,82 მლნ.
1,50 ათ.
1,50 ათ.
EBT including unusual items
-166,54 მლნ.
-166,54 მლნ.
17,91 მლნ.
17,91 მლნ.
EBT excluding unusual items
-167,61 მლნ.
-167,61 მლნ.
16,57 მლნ.
16,57 მლნ.
Income tax expense
9,50 ათ.
9,50 ათ.
139,50 ათ.
139,50 ათ.
Effective tax rate
-0,01%
-0,01%
0,78%
0,78%
Other operating expenses
-
-
-
-
Net income
-166,55 მლნ.
-166,55 მლნ.
17,77 მლნ.
17,77 მლნ.
Net profit margin
-1 157,28%
-1 157,28%
33,43%
33,43%
Earnings per share
-
-
-
-
Interest and investment income
1,29 მლნ.
1,29 მლნ.
3,89 მლნ.
3,89 მლნ.
Interest expense
-56,00 ათ.
-56,00 ათ.
-83,00 ათ.
-83,00 ათ.
Net interest expenses
1,24 მლნ.
1,24 მლნ.
3,81 მლნ.
3,81 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
-18,08 მლნ.
-18,08 მლნ.
14,89 მლნ.
14,89 მლნ.
Gain or loss from assets sale
63,50 ათ.
63,50 ათ.
-
-
AI content may include mistakes. Learn more
Google აპები